KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF
about
A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapyLeukocyte driven-decidual angiogenesis in early pregnancyIncidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis.Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.Renal involvement in preeclampsia: similarities to VEGF ablation therapyCombination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivoSmall molecule tyrosine kinase inhibitors: clinical development of anticancer agents.The expression and regulation of adrenomedullin in the human endometrium: a candidate for endometrial repair.Placenta growth factor expression is correlated with survival of patients with colorectal cancer.The Association between VEGFR Gene Polymorphisms and Stroke: A Meta-Analysis.VEGF Receptor-2-Linked PI3K/Calpain/SIRT1 Activation Mediates Retinal Arteriolar Dilations to VEGF and Shear Stress.Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humansAnti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancerTherapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertensionAngiogenesis and vasculogenesis: inducing the growth of new blood vessels and wound healing by stimulation of bone marrow-derived progenitor cell mobilization and homing.Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational studyImmune cells control skin lymphatic electrolyte homeostasis and blood pressureVEGF inhibition, hypertension, and renal toxicityHyperoxia, endothelial progenitor cell mobilization, and diabetic wound healingVascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function.Current thoughts on angiogenesis.Mode of action and clinical impact of VEGF signaling inhibitors.Prognostic significance of circulating and endothelial progenitor cell markers in type 2 diabetic foot.VEGF non-angiogenic functions in adult organ homeostasis: therapeutic implications.Cardiovascular safety and hemodynamic considerations in oncology drug development - webinar highlights October 10th 2012.Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration.In Situ Forming Gelatin Hydrogels-Directed Angiogenic Differentiation and Activity of Patient-Derived Human Mesenchymal Stem Cells.In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib.Selective stimulation of VEGFR2 accelerates progressive renal disease.Tyrosine phosphorylation modulates the vascular responses of mesenteric arteries from human colorectal tumors.Local tissue distribution and cellular fate of vascular endothelial growth factor (VEGF) following intramuscular injection.Vasodilator effect and mechanism of action of vascular endothelial growth factor in skin vasculature.PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.Bayesian methods for pharmacokinetic/pharmacodynamic modeling of pazopanib-induced increases in blood pressure and transaminases.Could precision-engineered peptide epitopes/vaccines be the key to a cancer cure?[Side effect management of tyrosine kinase inhibitors in urology : Hypertension].Vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and genistein-induced changes in the vascular reactivity of rat's aorta.Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence.
P2860
Q26824462-1D854222-E131-4E69-B787-A248D6CD22C7Q26851470-081E71F9-660F-46B8-8C05-AA27B05BBAEEQ30250303-65CD9189-63DE-4722-AE54-5DFE65A21BA3Q34499668-56D8E5D3-B094-4723-B9F3-8EE6392E5E8FQ34735646-FFABA48C-F3CB-4E77-B386-B8DE9410B5B5Q34787422-3988BEC2-3954-4DDE-93B5-E6025ECAF81DQ35040797-ACC856BA-E9DF-4CCC-8E10-0A5C63B67810Q35334720-3BF7CBB9-DFF1-4080-BF43-3F32DE878267Q35597339-0E2D7033-6260-4A24-8579-32A4321CFF8DQ35959083-F00D8A7F-7889-4E26-BBA4-D7D52C6AA271Q35980480-FD863595-3379-43D7-8E1B-ADEF6B85A721Q36100725-6767E36E-5F21-42C4-A91C-B79B67EA87ADQ36101895-C23F8EFE-783C-413F-ACCA-1CA801298609Q36388489-9CBD4A72-72EE-4D0D-A1DB-FA3408F78EC0Q36678295-44AB1255-78D7-4A8E-9B29-CE089AAD1645Q36837863-0BF51292-6CF6-48F6-BA5B-94C31A7D6352Q36858624-716F92F9-CE93-41AC-8AA7-75DDB2DF39F0Q36966854-1216E38F-B8AF-4307-AC2C-87E642CD461FQ37103555-E3B9EE2C-734D-48C5-B1CF-CA9C3068953FQ37216686-B7EE5D0A-1871-4332-9EDB-B7CD4953C407Q37291513-E9C49664-2E25-41BA-857D-F1752D59432CQ37365156-FFADD812-F5AC-46B3-9A45-BA0D22121ED7Q37483987-FAA2BCA7-3537-4A5B-AB33-403D4D9616B0Q37593811-607FD7FF-6834-4146-87F5-26E5E2339077Q37848687-631C18AF-3D69-4E32-88A2-A49657DDE015Q38104812-48FC769C-3D30-40E1-9226-8780B373C1C1Q40178858-A8702ACA-7B7A-4EB9-A3B2-D959948114D8Q41573721-4FC3C3E4-BC24-4C4C-BE6D-359E22017B49Q41773428-B849CBB2-B27F-415B-9E2D-3CD68AB90067Q42045011-CE877D6D-AF72-404B-BED8-68F0D7F83896Q42864506-91E35073-7694-4F75-8CD5-46B112E25CF9Q44176141-03B97DBE-DF1C-43A7-9770-6D134AC71813Q44673746-6C689F8C-D8EE-4A56-897A-F4B5BF62CFA2Q45293383-FD9E45FF-47F4-4CC1-99B7-41E725799F46Q50204127-9AF0FEEF-89BD-4CC2-B668-2D5E286794D2Q51265160-7D6935C4-BE35-40AE-8124-A52B6662830DQ51696685-A0A687D5-3DF1-44C4-85F8-F5EB48158B5CQ54195816-E0D4871D-67E0-48E6-9127-595B03DE3B09Q54319664-C44C5EC9-A3CF-473C-8D99-2FA9428F0DE3Q54578801-CB00A4C9-AFC6-413B-88DE-9EC84F391BE1
P2860
KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF
description
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2002
@ast
im Juni 2002 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2002/06/01)
@sk
vědecký článek publikovaný v roce 2002
@cs
wetenschappelijk artikel (gepubliceerd op 2002/06/01)
@nl
наукова стаття, опублікована в червні 2002
@uk
مقالة علمية (نشرت في يونيو 2002)
@ar
name
KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF
@ast
KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF
@en
KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF
@nl
type
label
KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF
@ast
KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF
@en
KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF
@nl
prefLabel
KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF
@ast
KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF
@en
KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF
@nl
P2093
P1433
P1476
KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF
@en
P2093
Abraham M. de Vos
Annie K. Ogasawara
Guo-Wei He
Hongkui Jin
Renhui Yang
Stuart Bunting
Thomas F. Zioncheck
P304
P356
10.1161/01.HYP.0000018588.56950.7A
P407
P577
2002-06-01T00:00:00Z